EUCTR2010-024454-10-GB进行中（未招募）不适用
An open label, phase II trial of afatinib with or without vinorelbine forthe treatment of HER2-overexpressing Inflammatory Breast Cancer
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •1. Female patients >=18 years with proven diagnosis of HER2-overexpressing, histologically confirmed breast cancer
- •2. Locally advanced or metastatic disease
- •3. Must have disease that can be evaluated according to RECIST 1.1 (Response Evaluation Criteria for Solid Tumours version 1.1)
- •4. For trastuzumab pre-treated patients, must have failed prior trastuzumab treatment
- •5. Investigator-confirmed diagnosis of Inflammatory Breast Cancer
- •6. Must have biopsiable disease
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 19
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 11
排除标准
- •1. Prior treatment with HER2-targeted small molecules or antibodies other than trastuzumab (which must have been given in the trastuzumab-failure study population)
- •2. Must not have received prior vinorelbine treatment
研究者
相似试验
Unknown
2 期
Phase II open label trial for Inflammatory Breast Cancer patients with Afatinib and/or Vinorelbine.CTRI/2012/01/002392Boehringer Ingelheim India Pvt Ltd40
进行中（未招募）
不适用
An open label trial of afatinib in treatment-naive (1st line) or chemotherapy pre-treated patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR mutation(s)Patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR mutation(s) and have never been treated with an EGFR-TKIMedDRA version: 14.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2009-017661-34-ESBoehringer Ingelheim España, S.A.500
进行中（未招募）
不适用
An open label trial of afatinib in treatment-naive (1st line) or chemotherapy pre-treated patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR mutation(s)Patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR mutation(s) and have never been treated with an EGFR-TKIMedDRA version: 14.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2009-017661-34-ITBoehringer Ingelheim500
进行中（未招募）
1 期
An open label trial of afatinib in treatment-naive (1st line) or chemotherapy pre-treated patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR mutation(s)EUCTR2009-017661-34-PTnilfarma - União Internacional de Lab. Farmacêuticos, Lda500
进行中（未招募）
1 期
An open label trial of afatinib in treatment-naive (1st line) or chemotherapy pre-treated patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR mutation(s)EUCTR2009-017661-34-HUBoehringer Ingelheim RCV GmbH & Co KG500